Services › Biosecurity Evaluation

2-week engagement · $10,000 – $20,000

Biosecurity Diligence Sprint

A two-week independent technical due-diligence engagement on a specific biosecurity, surveillance, or outbreak-forecasting product — for investors, agencies, and primes deciding who fills the gap left by the Ginkgo Biosecurity wind-down.

When this is the right engagement

You have a procurement or investment decision and the vendor's claims need an honest second read.

Wastewater surveillance vendors, metagenomic sequencing platforms, outbreak forecasting startups, AI triage tools for emerging diseases — the post-Ginkgo procurement window has more options than buyers can evaluate. The Diligence Sprint is for impact investors, public health agencies, and primes who need a structured, independent technical review on a two-week clock.

What you get

  • A structured diligence memo covering modeling validity, defensibility of claimed sensitivity and specificity, operational fit for the intended deployment context, and key risks.
  • A 60-minute debrief with the decision-maker.
  • Open evaluation framework, confidential application. The methodology used is public; the client-specific findings are confidential within the embargo terms.

How the engagement unfolds

Week 1

Materials review & vendor questions

Review the product brief, technical documentation, validation data, and any published claims. Submit a structured question list to the vendor where possible.

Week 2

Analysis & memo

Independent technical review against the published evaluation framework. Deliver the diligence memo. Hold the 60-minute decision-maker debrief.

What this engagement will not do

This is not a marketing review. If the conclusion is "the claimed sensitivity is not supported by the validation data presented," that is what the memo will say. Conflict-of-interest disclosure is part of every engagement. See Operating Principles.

Why this practitioner

Insider knowledge of what these systems actually deliver, applied honestly.

  • Former Senior Epidemiologist at Ginkgo Biosecurity (April 2024 – November 2025)
  • Prior leadership at The Public Health Company
  • Direct insider knowledge of what pathogen-surveillance, sequencing, and outbreak-forecasting systems actually deliver
  • Published evaluation framework, applied honestly